Pinnacle Clinical Research, PLLC

San Antonio, Texas 78229

1 studies enrolling now · 7 studies all time

What they study most

MASH, Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis, Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Steatohepatitis (NASH) With Fibrosis, Primary Biliary Cholangitis, Primary Biliary Cirrhosis

Studies at this site

• Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis — Recruiting now
• A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis — Running, not enrolling
• Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC) — Running, not enrolling
• RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA) — Completed
• Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) — Stopped early
• Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH) — Completed
• Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD) — Completed